BridgeBio Pharma BBIO Change in AR
Change in AR at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's change in ar.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's change in AR?
- BridgeBio Pharma (BBIO) reported change in AR of $65.78M in Q1 2026.
- How has BridgeBio Pharma's change in AR changed year-over-year?
- BridgeBio Pharma's change in AR decreased by 40.5% year-over-year, from $110.54M to $65.78M.
- What is the long-term trend for BridgeBio Pharma's change in AR?
- Over 2 years (2022 to 2024), BridgeBio Pharma's change in AR has grown at a -55.7% compound annual growth rate (CAGR), from -$15.17M to $2.97M.
- What does change in AR mean?
- The change in money owed to the company by its customers.
- How do you interpret change in AR?
- An increase consumes cash, while a decrease releases cash; rapid increases relative to revenue may signal collection issues.
- How does change in AR compare across companies?
- Highly dependent on the company's commercialization stage and customer payment terms.